GI Cancers Symposium

Analysis Supports Association Between TKI Response and Longer OS in HCC

January 22, 2019

Achieving an objective response to TKI therapy was associated with longer overall survival in patients with previously untreated hepatocellular carcinoma, according to findings of a retrospective analysis presented during the 2019 Gastrointestinal Cancers Symposium.

Promising CheckMate-142 Data for Second-Line Ipilimumab Plus Nivolumab in mCRC

January 22, 2019

Michael J. Overman, MD, discusses the data presented at the 2019 Gastrointestinal Cancers Symposium for the phase II CheckMate-142 in previously treated patients with microsatellite instability-high or mismatch repair-deficient metastatic colorectal cancer.

OS Increases With Checkpoint Inhibitor Doublet in Advanced Colorectal Cancer

January 21, 2019

When durvalumab and tremelimumab were combined with best supportive care, the combination reduced the risk of progression or death by 28% compared with best supportive care alone, according to findings from a phase II clinical trial.

Triplet Combo Improves Survival for BRAF V600E-Mutant mCRC

January 20, 2019

Updated findings from the safety lead-in phase of the BEACON CRC trial showed an estimated survival time beyond historic controls from treatment with a triplet combination of encorafenib, binimetinib, and cetuximab for patients with BRAF V600E-mutant metastatic colorectal cancer.

PFS Doubled With Regorafenib in Locally Advanced Biliary Tract Cancer

January 20, 2019

Regorafenib reduced the risk of progression by 51% compared with placebo in patients with metastatic or unresectable biliary tract cancer who were previously treated with gemcitabine and platinum-based chemotherapy, according to results from the phase II REACHIN trial that were presented at the 2019 Gastrointestinal Cancers Symposium.

BRAF V600E-Mutated Biliary Tract Cancer Benefits from BRAF/MEK Inhibition

January 19, 2019

Combined BRAF and MEK inhibition induced a promising response rate and survival rates among patients with BRAF V600E–mutated biliary tract cancer (BTC), according to the results of the ROAR trial that were presented during the 2019 Gastrointestinal Cancers Symposium.

OS Benefit From TAS-102 in Gastric Cancer Sustained in Subgroup Analysis

January 19, 2019

Treatment with TAS-102 led to an improvement in overall survival among patients with metastatic gastric/gastroesophageal junction cancer. The improvement was also seen both in patients who had and had not undergone prior gastrectomy, according to a subgroup analysis from the phase III TAGS study.

Next Steps After Phase III BEACON CRC Trial in mCRC

January 19, 2019

Pashtoon M. Kasi, MD, MBBS, MS, discusses how the triplet regimen of the BRAF inhibitor encorafenib, the MEK inhibitor binimetinib, and the EGFR inhibitor cetuximab, will impact the treatment landscape for patients with metastatic colorectal cancer.

Ramucirumab/Nivolumab Combination Active in Advanced Gastric Cancer

January 19, 2019

Based on findings from the phase I/II NivoRam study, investigators at the 2019 Gastrointestinal Cancers Symposium reported that the combination of nivolumab and ramucirumab is active in patients with previously treated advanced gastric adenocarcinoma.

Induction Regimen With Pembrolizumab/Trastuzumab Shows Benefit in HER2+ Gastric, GEJ Cancer

January 19, 2019

In findings reported at the 2019 Gastrointestinal Cancers Symposium, 67% of patients with untreated metastatic HER2-positive esophagogastric adenocarcinoma treated with the combination of pembrolizumab, trastuzumab, and chemotherapy remained progression-free at 6 months.